Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108

by @JTC_PALIdev | Jun 11, 2024 | Press Releases

PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end Carlsbad, CA, June 11, 2024 — Palisade Bio,...

Palisade Bio to Present at the Virtual Investor Pitch Conference

by @JTC_PALIdev | Jun 10, 2024 | Press Releases

Live video webcast on Monday, June 17th at 12:00 PM ET Carlsbad, CA, June 10, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel therapeutics for...

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

by @JTC_PALIdev | May 21, 2024 | Press Releases

Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure PALI-2108 exhibited a...

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

by @JTC_PALIdev | May 14, 2024 | Press Releases

– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Sufficient cash on hand to execute on business plan and reach clinical and regulatory...

Palisade Bio Appoints Margery Fischbein to its Board of Directors

by @JTC_PALIdev | May 7, 2024 | Press Releases

Wall Street and biotech industry veteran with expertise across corporate finance, business development, M&A, licensing, and strategic alliance transactions, globally Carlsbad, CA, May 07, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”,...